Categorynews

LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development

March 26, 2019 Off By BusinessWire

Unified applications for clinical, regulatory, and quality streamline
end-to-end product development to increase operational efficiency

BARCELONA, Spain–(BUSINESS WIRE)–Veeva
Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader
in medical dermatology, selected Veeva
Development Cloud applications to help drive end-to-end business
processes across product development. The company will utilize the Vault
Clinical, Vault
RIM, and Vault
Quality suites to unify drug development on a single cloud platform.
With Veeva Development Cloud, LEO Pharma can bring together applications
for clinical, regulatory, and quality for even greater efficiency and
compliance throughout the product development lifecycle.

“LEO Pharma R&D has embarked on an ambitious strategy for 2025, which
will pave the way for our ambitions to continuously pioneer dermatology.
This requires that we are able to drive science globally, whilst at the
same time securing timely delivery on our pipeline,” said Kim Kjøller,
executive vice president of global research and development at LEO
Pharma. “Veeva Development Cloud gives us a unified platform that can
enable us to maximize efficiency throughout product development and
scale as we grow towards our goals. Now we will be able to streamline
product development globally and speed up delivery of new treatments to
even more patients.”

LEO Pharma aims to reach 125 million patients who have chronic and acute
skin conditions by 2025. To expand its drug development efforts, the
company has made a number of significant acquisitions and established
hubs in the United States and China. Veeva Development Cloud gives LEO
Pharma’s global teams a single source for product development
information to better maintain compliance and improve global
collaboration.

“Veeva is helping us transform our entire R&D business,” said Mika
Välilä, senior director of digital business platforms, global IT, for
LEO Pharma. “Veeva Development Cloud allows us to drive greater
consistency and productivity across product development efforts in
clinical trials, regulatory matters, and quality.”

LEO Pharma today utilizes Vault
eTMF, Vault
Submissions, and Vault
QualityDocs. In 2019, the company will add Vault
CTMS, Vault
Study Startup, Vault
Registrations, and Vault
QMS to further streamline the product development lifecycle across
regions and departments.

“LEO Pharma is a great example of how organizations are modernizing
critical business functions,” said Rik Van Mol, vice president of Veeva
Development Cloud Strategy, Europe at Veeva. “Veeva Development Cloud
gives life sciences companies the foundation to eliminate system, site,
and country silos throughout drug development.”

Hear LEO Pharma and other customers discuss why they are standardizing
on Veeva Development Cloud at the upcoming Veeva
R&D Summit, Europe, June 11-13, 2019, Barcelona, Spain. See the
agenda and register at veeva.com/eu/events/rd-summit.

Additional Information

For more on Veeva Development Cloud, visit: veeva.com/development-cloud

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veeva_eu on Twitter: twitter.com/veeva_eu

Like Veeva on Facebook: facebook.com/veevasystems

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in
medical dermatology with a robust R&D pipeline, a wide range of
therapies, and a pioneering spirit. Founded in 1908 and owned by the LEO
Foundation, LEO Pharma has devoted decades of research and development
to advance the science of dermatology, setting new standards of care for
people with skin conditions. LEO Pharma is headquartered in Denmark with
a global team of 5,500 people, serving 76 million patients in 130
countries. In 2018, the company generated net sales of DKK 10,410
million. For more information, go to www.linkedin.com/company/leo-pharma or www.leo-pharma.com.

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva serves more than 700 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,
visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2018. This is available on the
company’s website at veeva.com under
the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.